Phase 3Data readout

Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin)

Niemann-Pick Disease Type C1 (NPC1)

RFLRafael Holdings Inc

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin)
Development stage: Phase 3
Event type: Data readout
Indication: Niemann-Pick Disease Type C1 (NPC1)

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in Niemann-Pick Disease Type C1 (NPC1). The expected timing is based on the latest available company guidance and may change.

Development notes

06/11/26:- TransportNPC pre-NDA meeting completed. NDA submission expected H2 2026; Ph3 topline data expected Q3 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source